Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Labidocera madurae

ABSTRACT: Labidocera madurae Transcriptome or Gene expression

PROVIDER: PRJNA324849 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5922844_1.fastq.gz	Fastqsanger.gz
	SRR5922844_2.fastq.gz	Fastqsanger.gz
	SRR5922845_1.fastq.gz	Fastqsanger.gz
	SRR5922845_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Actinomadura madurae

Project description:Actinomadura madurae overview

| PRJNA172799 | ENA

Actinomadura madurae NBRC 14623

Project description:Actinomadura madurae NBRC 14623 genome sequencing project

| PRJDB387 | ENA

Actinomadura madurae strain:dsm 43067

Project description:Actinomadura madurae DSM 43067 genome sequencing

| PRJNA303645 | ENA

Actinomadura madurae LIID-AJ290

Project description:Actinomadura madurae LIID-AJ290 Genome sequencing and assembly

| PRJNA217416 | ENA

Actinomadura madurae strain:ATCC 19425

Project description:Actinomadura madurae strain:ATCC 19425 Genome sequencing

| PRJNA760936 | ENA

Molecular diagnosis of Actinomadura madurae infection by 16S rRNA deep sequencing.

Project description:Next-generation DNA sequencing can be used to catalog individual organisms within complex, polymicrobial specimens. Here, we utilized deep sequencing of 16S rRNA to implicate Actinomadura madurae as the cause of mycetoma in a diabetic patient when culture and conventional molecular methods were overwhelmed by overgrowth of other organisms.

| S-EPMC3838028 | biostudies-literature

Project description:Actinomadura madurae DSM 43067

| PRJEB17130 | ENA

Biomarks of Resistance to Cetuximab in Colorectal Cancer

Project description:Interventions: A group:Before using cetuximab;B group:After progression of disease:no Primary outcome(s): KRAS gene sequence;NRAS gene sequence;BRAF gene sequence;PIK3CA gene sequence;EGFR gene sequence;EGFR gene copy numbers;EGFR expression;Her2 expression;c-Met expression;PTEN expression Study Design: historical control

| 2671639 | ecrin-mdr-crc

TR study of ‘multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer&quot

Project description:Primary outcome(s): Cancer-related gene alteration, expression of protein, and expression of RNA

| 2645675 | ecrin-mdr-crc

TR study of ‘A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer (BRAVERY study)&quot

Project description:Primary outcome(s): cancer-related gene alteration, gene expression, microsatellite instability, BRAF mutant allele frequency

| 2646701 | ecrin-mdr-crc